<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; deal</title>
	<atom:link href="http://www.tapanray.in/tag/deal/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>No Compromise: India Protects Patents Act in High-Stakes UK Trade Pact</title>
		<link>http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact</link>
		<comments>http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/#comments</comments>
		<pubDate>Wed, 30 Jul 2025 06:47:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2025]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[data exclusivity]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ever greening]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[no compromise]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safeguards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[UK]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10948</guid>
		<description><![CDATA[India, the &#8220;pharmacy of the world,&#8221; has long been a lifeline for millions, churning out affordable generic medicines that make healthcare accessible across the Global South. With over $25 billion generic drug industry exporting half its production, India’s commitment to &#8230; <a href="http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Innovation and Pharma M&amp;As: A Recent Perspective</title>
		<link>http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-innovation-and-pharma-mas-a-recent-perspective</link>
		<comments>http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/#comments</comments>
		<pubDate>Mon, 04 Jun 2018 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[hefty]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[objectives]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8949</guid>
		<description><![CDATA[The 21st CEO Survey 2018 of PwC highlights a curious contradiction. This is based on what the Global Pharma Chief Executive Officers (CEOs) had articulated regarding their business outlook for 2018 and beyond. The report says: Despite highly publicized hand &#8230; <a href="http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>R&amp;D: Is Indian Pharma Moving Up the Value Chain?</title>
		<link>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rd-is-indian-pharma-moving-up-the-value-chain</link>
		<comments>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/#comments</comments>
		<pubDate>Mon, 02 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[analogue]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[Cadilla]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[diabetic]]></category>
		<category><![CDATA[Dr]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[dyslipidemia]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[falciparum]]></category>
		<category><![CDATA[Forest]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glitazar]]></category>
		<category><![CDATA[hibernation]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Jubilant]]></category>
		<category><![CDATA[lab]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Lipaglyn]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[mass]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[plasmodium]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy's]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Rotavac]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Synrium]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Torrent]]></category>
		<category><![CDATA[universities]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3530</guid>
		<description><![CDATA[It almost went unnoticed by many, when in the post product patent regime, Ranbaxy launched its first homegrown ‘New Drug’ of India, Synriam, on April 25, 2012, coinciding with the ‘World Malaria Day’. The drug is used in the treatment &#8230; <a href="http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer and Biocon deal – heralds dawn of a new era for the Biopharmaceuticals Industry of India</title>
		<link>http://www.tapanray.in/pfizer-and-biocon-deal-heralds-dawn-of-a-new-era-for-the-biopharmaceuticals-industry-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pfizer-and-biocon-deal-heralds-dawn-of-a-new-era-for-the-biopharmaceuticals-industry-of-india</link>
		<comments>http://www.tapanray.in/pfizer-and-biocon-deal-heralds-dawn-of-a-new-era-for-the-biopharmaceuticals-industry-of-india/#comments</comments>
		<pubDate>Thu, 25 Nov 2010 03:41:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[analogue]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biopharmaceutical]]></category>
		<category><![CDATA[dawn]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[era]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[heralds]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[insulin]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=357</guid>
		<description><![CDATA[On October 19, 2010, home grown Biotech Company Biocon, based in the IT heartland – Bangalore created a stir in Industry by inking an interesting international corporate business deal with the largest global pharmaceutical company &#8211; Pfizer. The deal will &#8230; <a href="http://www.tapanray.in/pfizer-and-biocon-deal-heralds-dawn-of-a-new-era-for-the-biopharmaceuticals-industry-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pfizer-and-biocon-deal-heralds-dawn-of-a-new-era-for-the-biopharmaceuticals-industry-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Abbott – Piramal deal: the way future is expected to shape up</title>
		<link>http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=abbott-piramal-deal-the-way-future-is-expected-to-shape-up</link>
		<comments>http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/#comments</comments>
		<pubDate>Mon, 31 May 2010 01:30:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[expected]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[monopoly]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[valuation]]></category>
		<category><![CDATA[way]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=421</guid>
		<description><![CDATA[In my view, these are still very early days for such acquisitions of large domestic Indian pharmaceutical companies by the Global Pharma majors to gain momentum in the country. However, there is no doubt that in the near future, we &#8230; <a href="http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
